David Kyle, PhD
Serving as the Chief Scientific Officer of Evolve BioSystems, David is a 30 year veteran of biotech, having co-founded a range of successful biotech companies in the fields of nutrition and health, including Martek Biosciences, which was acquired in 2011 for $1.1 Billion). David combines a strong scientific background with significant commercial acumen, has published over 70 scientific articles, edited two books, and is the named inventor on over 80 patents.
Daniel Janney, MBA
Dan is the Managing Director of Alta Partners, a leading venture capital firm in life sciences, funding over 145 companies in the industry since 1996. Dan joined Alta immediately following the firm’s founding, and was co-founder of the Alta BioPharma effort. Dan focuses on investments in biopharmaceutical products and therapeutics and has been directly involved in the funding and development of over 25 life sciences companies. Dan is currently on the Board of Directors of a number of companies, including Alba Therapeutics, Esperion Therapeutics, Lithera, Prolacta Bioscience, and ViroBay. In addition, he led Alta’s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, DiscoveRx, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.
Simon Barnes, PhD, MBA
Simon Barnes is a Partner of Circadia Ventures and manages a venture capital fund backed by the global ingredient company Tate & Lyle. Simon has spent 15 years in and around the life sciences venture capital industry, first with the London office of Atlas Venture and subsequently with GIMV Venture Capital. He has served on a number of VC-backed boards from early stage to exit including Allylix (USA), Fugeia (Belgium) and Lumora (UK). Simon has a first class honors degree in Natural Sciences and a PhD from The University of Cambridge, UK. He spent two years as a Research Fellow at The Rockefeller University in New York, before becoming Head of The Laboratory of Cotton Biotechnology in Singapore. He holds an MBA with Distinction from Imperial College London, later joining the faculty and becoming Director of Imperial's Entrepreneurship Centre prior to co-founding Circadia Ventures in 2006.
Roger Wyse, PhD
Dr. Roger Wise is Founder & Managing Partner of Spruce Capital Partners. He also currently serves on the International Advisory Panel for Biotechnology (BioIAP) and is a member of the Global Science and Innovation Advisory Council for the Prime Minister of Malaysia. Dr. Wyse is a member of the Civilian Research and Development Foundation’s GIST Global Advisory Group, and is the former President and COO, Venture Capital and Private Equity Funds (Biogreentech), at Burrill & Company. Dr. Wyse has over 30 years of experience as an internationally recognized scientist and as a Dean at two major research universities: Rutgers and the University of Wisconsin-Madison.
Gareth Asten, MBA
Gareth is a Co-Founder and Managing Partner of Acre Venture Partners, a Santa Monica, CA based venture fund primarily focused on disruptive technologies, products and services for better outcomes in the food system. Prior to founding Acre, Gareth was a key executive team member in three leveraged buyouts, including Bolthouse Farms (sold to the Campbell Soup Company). Gareth holds a BS in Finance from DePaul University and an MBA from Harvard Business School. He is also a Trustee for PS1 Pluralistic Elementary School in Santa Monica, CA, is on the Advisory Board for the Southern California Food Allergy Institute and is a Board Member of Kiss the Ground, a non-profit focused on educating consumers and farmers on the benefits of regenerative farming practices.
Patrick Zhang, MBA
Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology, healthcare and fintech investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M&A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.
Timothy B. Brown, MBA
Serving as CEO of Evolve BioSystems, Tim brings over 25 years of experience in the global consumer goods and pediatric nutrition industries, most notably with companies including Mead Johnson Nutrition and Procter & Gamble. Following his time as a US Naval officer, Tim was able to launch a range of new, innovative products in the developed and developing world, many of which remain leaders in their respective categories today.